Second recently disclosed open market purchase brings CEO’s direct ownership to more than 23.2 million shares

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) — Eva Live Inc. (Nasdaq: GOAI) (“Eva Live” or the “Company”) today announced that its Chief Executive Officer, David Boulette, purchased an additional 19,800 shares of the Company’s common stock in the open market at a price of $2.01 per share, representing a personal cash investment of $39,798.

The transaction occurred on September 25, 2026, and was disclosed in a Form 4 filed with the U.S. Securities and Exchange Commission on September 28, 2026. Following the purchase, Mr. Boulette directly owns 23,266,225 shares of Eva Live common stock.

The purchase follows Mr. Boulette’s September 22, 2026 open market acquisition of 18,478 shares at an average price of approximately $2.03 per share. Together, the two recent open market purchases represent 38,278 additional shares and a combined personal cash investment of approximately $77,308.

“I continue to purchase GOAI shares in the open market because I believe strongly in the Company, our technology and the opportunities ahead of us,” said David Boulette, Chief Executive Officer of Eva Live. “As CEO and a major shareholder, my interests are directly aligned with those of every GOAI shareholder. I am investing my own capital because I believe the current market valuation does not reflect the long-term potential of the businesses and technology we are building.”

Mr. Boulette added, “Our team remains focused on execution, expanding our revenue-generating businesses and commercializing our technology across artificial intelligence, digital marketing, lead generation and emerging growth markets. I believe Eva Live is entering an important stage of its development, and I intend to remain closely aligned with our shareholders as we work to build long-term value.”

The purchase represents Mr. Boulette’s second recently disclosed open market acquisition and follows the Company’s September 23 announcement regarding his acquisition of more than 4.22 million shares through a combination of an option exercise, stock issued for accrued compensation and an open market purchase.

Management believes Mr. Boulette’s substantial ownership position demonstrates a strong alignment between Company leadership and shareholders. Eva Live remains focused on disciplined execution, commercial growth and the continued development of its portfolio of technology-driven businesses.

About Eva Live Inc.

Eva Live Inc. (NASDAQ: GOAI) is an artificial intelligence technology company developing and commercializing AI-powered platforms across multiple industries. Through Eva Defense Inc., the Company is applying its artificial intelligence technology to autonomous systems, unmanned platforms, communications and next-generation defense applications.

For more information, visit www.eva.live

Cautionary Note Regarding Forward-Looking Statements.

This press release contains “forward-looking statements” within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included herein, including but not limited to such things as future business strategy, plans, and goals, and the expansion and growth of our business. The words “estimate”, “plan”, “anticipate”, “expect”, “intend”, “believe” “target”, “budget”, “may”, “can”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to” and similar words or expressions, or negatives of these terms or other variations of these terms or comparable language or any discussion of strategy or intention identify forward-looking statements. Please see the risk factors included in the Company’s United States Securities and Exchange Commission filings, which could cause actual results and events to differ materially from those contained in the forward-looking statements. You are cautioned against attributing undue certainty to forward-looking statements. Although these forward-looking statements were based on assumptions that the Company believes are reasonable when made, you are cautioned that forward-looking statements are not guarantees of future performance and that actual results, performance, or achievements may differ materially from those made in or suggested by the forward-looking statements in this press release. Any forward-looking statements made in this press release speak only as of the date of those statements. We undertake no obligation to update those statements or publicly announce the results of any revisions to any of those statements to reflect future events or developments.

Media Inquiries:
Javan Khazali
Phone: 310-229-5981
Email: info@eva.live

Website: @eva.live
Instagram: @eva.liveinc
Facebook: @evaliveinc
X: @evaliveinc1
LinkedIn: @eva-live
Youtube: @evaliveinc

WisdomTree Multi Asset Issuer Public Limited Company
LEI: 2138003QW2ZAYZODBU23
29 September 2026
WisdomTree Multi Asset Issuer Public Limited Company
(a public company incorporated with limited liability in Ireland)
Collateralised ETP Securities Programme
Interim Report and Unaudited Financial Statements as of 30 June 2026
To view the full document, please paste the following URL into the address bar of your browser.
https://www.wisdomtree.com/gb/media/unaudited-interim-financial-statements-30-june-2026
For further information please contact Europesupport@wisdomtree.com

Attachment

Leveraging its approximately 200,000 estimated paid-member base, SunCare begins rolling out its RMB 500-per-month Essential Health Management service under a three-tier AI-powered senior care subscription framework, with planned RMB 1,990 Enhanced Home Health and Care Services and RMB 2,990 Advanced Assisted Care tiers

YANTAI, China, Sept. 29, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (“Decent” or the “Company”), a technology-driven provider of wastewater treatment and community-based senior health and elderly care services in China, today announced that its SunCare senior care business has launched an RMB 500-per-month AI-powered in-home senior care service, supported by a strategic collaboration with Ruilan International and leveraging SunCare’s existing base of approximately 200,000 estimated paid members.

The rollout represents an important step in SunCare’s strategy to extend its community-based senior care network directly into seniors’ homes and develop a recurring-service model integrating intelligent devices, health monitoring, AI-enabled care management and offline senior-care services.

Under the collaboration, Ruilan International will provide intelligent senior-care equipment and related technology infrastructure for deployment through SunCare’s community network and into participating households. The cooperation encompasses intelligent health monitoring equipment, medical and nursing support robots, in-home service robots, rehabilitation equipment and related intelligent senior-care systems.

Extending Senior Care into the Home

Through in-home intelligent devices and monitoring systems, SunCare intends to connect participating seniors directly with its broader community-based senior-care infrastructure. Depending on the applicable service configuration, the system is designed to support monitoring and management of health-related information, including blood pressure, blood oxygen and sleep, together with AI-assisted health management, abnormal-condition alerts and community-based service support.

SunCare plans to use its community locations as local service nodes for equipment deployment, member engagement, health management and related senior-care services, creating an integrated service network connecting participating households, intelligent devices, health information and community services.

Three-Tier Subscription Framework

The RMB 500 monthly service represents the initial commercial rollout of SunCare’s three-tier subscription framework:

Essential Health Management — approximately RMB 500 per month. The entry-level service is designed for relatively independent seniors seeking ongoing health and wellness management, including personal health profiles, authorized data collection through wearable and home monitoring devices, AI-assisted health information analysis, wellness reminders, abnormal-condition alerts, designated community services and family notifications.

Enhanced Home Health and Care Services — approximately RMB 1,990 per month. This planned tier is expected to add more frequent health and wellness monitoring, home-based support, enhanced family communication, personalized service coordination and access to participating healthcare and elderly care service providers.

Advanced Assisted Care — approximately RMB 2,990 per month. This planned tier is intended for seniors requiring higher-frequency daily support and is expected to include enhanced home monitoring, fall and abnormal-condition alerts, priority home-service coordination, intelligent robotic and assistive technologies where available, and coordination with qualified healthcare and elderly care service providers.

SunCare has begun rolling out the RMB 500 Essential Health Management service and intends to progressively introduce the planned higher-tier services as its technology deployment and service capabilities expand.

The rollout is being introduced to SunCare’s existing base of approximately 200,000 estimated paid members. This figure represents management’s current estimate of SunCare’s existing paid-member base and should not be interpreted as the number of members who have subscribed to the new RMB 500 service or any planned higher-tier services.

Building an AI-Powered Senior Care Ecosystem

By combining SunCare’s community and member reach with Ruilan International’s intelligent senior-care equipment and technology capabilities, the Company intends to build a distributed senior-care infrastructure connecting community locations, households, intelligent devices, health information and service personnel.

The model is designed to support recurring service relationships rather than relying solely on one-time equipment sales, while providing a foundation for additional subscription and value-added services as SunCare’s AI-powered senior care platform develops.

“Senior care is increasingly moving beyond traditional facilities and into the home,” said Haicheng XU, Chief Executive Officer of Decent Holding Inc. “By combining our existing member and community network with intelligent devices and AI-enabled health management, we are working to create a scalable senior-care service platform that connects directly with seniors in their homes. The launch of our RMB 500 monthly service represents an important first step in this strategy.”

About Decent Holding Inc.

Decent Holding Inc. specializes in providing wastewater treatment services by cleansing industrial wastewater, ecological river restoration, and river ecosystem management. Through its subsidiaries, the Company also continues to develop community-based senior health and elderly care services and technology-enabled senior-care solutions in China.

For more information, please visit the Company’s website: https://ir.dxshengtai.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including statements regarding the Company’s plans to expand its senior-care services, deploy intelligent devices into participating households, develop subscription-based services, introduce additional service tiers and develop its AI-powered senior care platform. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations regarding future events. Investors can identify these statements by words or phrases such as “plans,” “expects,” “intends,” “believes,” “will,” “may,” “could,” “potential,” and similar expressions. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

Investor Relations Contact:
WFS Investor Relations Inc.
Connie Kang, Partner
Email: ckang@wfsir.com
Tel: +86 1381 185 7742 (CN)

Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype that will respond to immune-based intervention

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an immunologically inactive liver cancer tumor microenvironment into one that is immunologically active and potentially susceptible to immune-based therapy. The academic paper titled “MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma” was published in Proceedings of the National Academy of Sciences on September 28, 2026 (link to the paper). Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.

“This publication provides additional evidence that pelareorep alters the tumor microenvironment in traditionally challenging indications,” said Thomas Heineman, MD, PhD, Chief Medical Officer of Oncolytics. “The ability to enable chemotherapy, checkpoint inhibitors, RAS inhibitors, and other treatments to be viable in cancers that have previously been untreatable is helping to drive our business development conversations. While liver cancer is not an indication we intend to pursue at this time, the data align with our narrative that pelareorep works in challenging tumor types and can be considered a backbone immunotherapy that can improve the activity of many cancer treatments, while maintaining a favorable safety profile.”

Hepatocellular carcinoma tends to have low levels of CD8+ T cell infiltration and Inducible T cell Costimulatory Ligand (“ICOSL”) in addition to high levels of Transforming Growth Factor Beta / Suppressor of Cytokine Signaling 1 / Yes-associated protein 1, which are signs of a significantly immunosuppressive tumor microenvironment. Preclinical data presented in this publication show that infection with pelareorep reversed several of these effects, including dramatic increases in PD-L1 expression, ICOSL levels on tumor cells, and CD8+ T cell density. These changes imply the tumor microenvironment shifted from immunologically inactive or “cold” to “hot” or immunologically active, enabling immune-mediated lysis of tumor cells.

This cascade of immune responses creates an environment in which checkpoint inhibitors and other therapies can be effective. Pelareorep has previously shown the ability to initiate coordinated changes in the tumor microenvironment, including the formation of tertiary lymphoid structures, that are associated with improved responses to immunotherapy. In this paper, there is a noted increase in CD8+ T cells, PD-1/PD-L1 upregulation, and Inducible T cell Co-stimulator-ICOSL signaling. These are all necessary conditions for immunotherapies like checkpoint inhibitors to work in liver cancer, which is an especially challenging tumor type.

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies, its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; implications of the preclinical data from the publication; the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers; and plans for future disclosure of clinical trial results. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com

New York, Sept. 29, 2026 (GLOBE NEWSWIRE) — Columbus Acquisition Corp (the “Company”), a blank check company, today announced that it reconvened its Extraordinary General Meeting of the Shareholders (the “Meeting”) and, without conducting any business, adjourned the Meeting to 9:30 a.m. Eastern Time on September 30, 2026 at the offices of Loeb & Loeb LLP, 345 Park Avenue, New York, NY 10154, and virtually via teleconference using the following dial-in information:

Telephone access:
Within the U.S.: and Canada: 1 800-450-7155 (toll-free)
Outside of the U.S. and Canada: +1 857-999-9155 (standard rates apply)
Phone conference ID: 5870682#

The Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on August 19, 2026, including any amendments or supplements thereto (the “Proxy Statement”), including the proposal to approve the proposed business combination with WISeSat.Space Corp. Except for the meeting date and time provided above, the Company’s previously announced information concerning the Meeting remains unchanged.

The record date for determining the Company shareholders entitled to receive notice of and to vote at the Meeting remains the close of business on August 17, 2026 (the “Record Date”). Shareholders as of the Record Date are eligible to vote, even if they have subsequently sold their shares.

If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal.

If you have already submitted a proxy and do not wish to change your vote, you need not take any further action. If you have submitted a proxy and wish to change your vote, you may revoke your proxy at any time before it is exercised at the Meeting as provided in the Proxy Statement. Please note, however, that if your shares are held in street name by a broker or other nominee and you wish to revoke a proxy, you must contact the broker or nominee to revoke any prior voting instructions.

The Company’s shareholders who have questions regarding the adjournment, or the Meeting, or would like to request documents may contact the Company’s proxy solicitor, Advantage Proxy, Inc., at:

Advantage Proxy, Inc. P.O. Box 10904
Yakima, WA 98909
Individuals call toll-free 1-877-870-8565
Banks and brokers call 1-206-870-8565
Email: ksmith@advantageproxy.com

In addition, shareholders who have already submitted a redemption request with respect to the shares held by them may withdraw such request by contacting our transfer agent. If you would like to change or revoke your prior vote on any proposal, or reverse a redemption request, please refer to the Proxy Statement for additional information on how to do so.

About Columbus Acquisition Corp

Columbus Acquisition Corp is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Columbus is led by Fen “Eric” Zhang, Chairman and Chief Executive Officer, and Jie “Janet” Hu, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries. 

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including but not limited to the date of the Meeting, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Additional Information and Where to Find It

On August 19, 2026, the Company filed a definitive proxy statement with the SEC in connection with its solicitation of proxies for the Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (including any amendments or supplements thereto) and other documents filed with the SEC through the website maintained by the SEC at www.sec.gov or by contacting the Company’s proxy solicitor.

Participants in the Solicitation

The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement. You may obtain free copies of these documents using the sources indicated above.

Contact

Fen Zhang
Chairman and Chief Executive Officer
Email: eric.zhang@herculescapital.group

Tel: (+1) 949 899 1827 

Sheridan joins independent journalist Nick Shirley to discuss how Nutriband’s AVERSA™ abuse-deterrent technology is designed to help reduce the abuse, misuse, and accidental exposure driving the ongoing epidemic

ORLANDO, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its CEO, Gareth Sheridan, has been featured in a new documentary by independent journalist and filmmaker Nick Shirley examining the ongoing opioid crisis in the United States. Shirley, turns his lens in this latest piece to the devastating impact of illegal opioid abuse on individuals and communities across the country — and the complex challenges surrounding some of the nation’s most commonly abused prescription medications.

Sheridan participated in the documentary to bring a pharmaceutical innovation perspective to the conversation, discussing how technologies such as Nutriband’s AVERSA™ abuse-deterrent platform are designed to help reduce the risk of abuse, misuse, diversion, and accidental exposure associated with high-risk medications — while working to preserve access for the patients who depend on them for legitimate medical need.

“The opioid crisis isn’t an abstraction — it’s a daily reality for families across this country, on both sides of addiction and genuine pain, and it demands real solutions,” said Gareth Sheridan, CEO of Nutriband. “I was glad to work with Nick and speak plainly about where pharmaceutical innovation fits into that fight. AVERSA™ was built specifically to address this problem: giving patients who need these medications access to them, while making them fundamentally harder to abuse, misuse, or divert for people suffering from addiction or from accidental exposure.”

The full documentary is available to view here: https://youtu.be/zyDQOBp4nn4

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

New system-of-systems orchestration lab at Invest Ottawa’s Area X.O will connect legacy and emerging technologies accelerating development to deployment for Canada’s sovereign capabilities

OTTAWA, Ontario, Sept. 29, 2026 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY) and Invest Ottawa today announced the launch of the Northstar Defence Lab at Area X.O during GCXpo, Canada’s next-generation technology demonstration showcase. The Northstar Defence Lab is a new mission-orchestration environment designed to address one of Canada’s most urgent defence challenges: enabling technologies developed by multiple innovators and companies, for different platforms and missions, to securely share data, coordinate action and operate as one integrated system of systems.

Canada must keep pace with rapidly changing technology and threats by unifying new and legacy defence capabilities while maintaining interoperability across the Canadian Armed Forces (CAF) and with its allies. Located at Area X.O’s Greenbelt site in Ottawa, the Northstar Defence Lab will provide a persistent Canadian environment where technologies can be integrated, orchestrated, tested, technically validated and scaled safely as part of a broader system of systems.

Developed by Calian in partnership with Area X.O, founded and operated by Invest Ottawa, and powered by Calian ATHORA™, the Lab will bring together Calian VENTURES’ partners, Canadian innovators, defence OEMs, defence solutions and technology partners to build integrated capabilities for Canada.

“Calian has supported Canada’s defence community for decades, delivering mission-critical capabilities where readiness, resilience and interoperability matter most,” said Patrick Houston, Chief Executive Officer, Calian. “As the Canadian Armed Forces modernizes to meet evolving threats, we are investing in the technologies, companies and collaborative infrastructure needed to move at pace alongside them. Through Calian VENTURES and the Northstar Defence Lab, we are helping strengthen Canada’s defence industrial base and accelerate the development, validation and deployment of integrated mission capabilities.”

The Northstar Defence Lab will be the first facility in Calian’s planned nationwide network of regional defence development labs. It is also a tangible next step in the company’s initiative to mobilize an initial $100 million to accelerate sovereign Canadian C5ISRT capabilities.

Orchestrating a collaborative Canadian defence ecosystem

Northstar will be established at Area X.O’s Greenbelt campus, a next-generation R&D complex and NATO DIANA Test Centre, with its real-world testing environments and connections across Canada’s defence and dual-use innovation ecosystem. Calian will build and operate the Northstar Defence Lab and serve as its defence integrator and orchestrator, applying its defence expertise, partner network and system-of-systems integration capabilities.

Its founding ecosystem partners include ADGA, Anvil, Cohere, Evertz Microsystems Limited, Larus, TACTIQL, Tessellate Robotics and 123 Cyber with Export Development Canada participating as an industry commercialization partner. Together, Northstar’s defence and technology partners will contribute complementary Canadian capabilities and expertise in communications, data fusion, artificial intelligence, cyber, sensing and operational decision support to help strengthen the CAF’s platforms and mission systems. The Lab will remain open to Calian’s existing and expanding network of Calian VENTURES partners.

“Northstar is being designed around the mission, not around any one product or company,” said Chris Pogue, President, Defence and Space, Calian. “It will give defence partners a place to connect legacy and emerging technologies, identify interoperability gaps and validate how the complete system of systems performs in the kind of realistic operational environment that is essential for Canada to move new capabilities toward operations at the pace required.”

“Canada’s ability to strengthen its sovereignty, security and economic resilience depends on turning homegrown innovation into real-world capability,” said Sonya Shorey, President and CEO, Invest Ottawa. “Through Area X.O and Ottawa’s innovation ecosystem, we are bringing together founders, companies, government, our Forces, and partners to accelerate the validation, adoption and deployment of defence and dual-use technologies, helping Canadian companies get to market, customers and revenue faster. The Northstar Defence Lab at Area X.O will help strengthen this pathway, creating new opportunities for Canadian companies, building our defence industrial capacity, and continually increasing the impact of Canada’s Capital Region as a national and global defence innovation hub serving Canada, our Forces and allies.”

The Northstar Defence Lab at Area X.O will be powered by ATHORA, a sovereign system-of-systems interoperability and mission-orchestration platform. Northstar will give Canadian innovators and small and medium-sized enterprises a pathway to demonstrate how their intellectual property can contribute to larger defence solutions.

Through Northstar, Calian and Invest Ottawa are creating a persistent Canadian environment where the defence ecosystem can turn disconnected technologies into integrated mission capability, faster. The result will be stronger system-of-systems interoperability, faster capability adoption and greater Canadian control over the technologies essential to operational readiness, Arctic sovereignty and national security.

About Calian

www.calian.com

For over 40 years, Calian has delivered mission-critical solutions when failure is not an option. Trusted worldwide, we empower organizations in critical industries to overcome obstacles, manage risks and drive progress. By combining the expertise of our people, proven industry insight, cutting-edge technology, bold innovation and global reach, we deliver tailored solutions that solve complex challenges. Headquartered in Ottawa, Canada, with over 6,000 people around the world, Calian’s solutions protect lives, strengthen security, foster global connectivity and drive economic progress, making a lasting impact where and when it matters most.

For additional information, visit calian.com.

Product or service names mentioned herein may be the trademarks of their respective owners.

Media inquiries
media@calian.com
613-599-8600

Investor Relations inquiries
ir@calian.com

About Invest Ottawa and Area X.O

Invest Ottawa
Lindsey Fair
Vice President, Marketing and Bayview Impact
Invest Ottawa, Area X.O and Bayview Yards
613.857.7779
Lfair@investottawa.ca

About Invest Ottawa, Area X.O and GCXpo 

Invest Ottawa is the lead economic development agency for knowledge-based industries in Canada’s Capital and the founder and operator of Area X.O, a next-generation R&D complex and NATO DIANA Test Centre that helps innovators, entrepreneurs and companies get to market faster and safely by working directly with end users. Through Area X.O at the Greenbelt in Ottawa and Killaloe in the Ottawa Valley, Invest Ottawa brings together entrepreneurs, startups, SMEs, multinationals, governments, prospective customers, regulators and collaborators to safely develop, test, validate, demonstrate and commercialize breakthrough technologies in real-world conditions, driving adoption and deployment. Area X.O also hosts GCXpo, Canada’s premier next-generation technology demonstration event, bringing together innovators, companies, government and industry leaders, investors, researchers, and ecosystem partners across defence, agtech, smart mobility and other dual-use technologies to accelerate commercialization, adoption, deployment, and global growth.

DISCLAIMER

Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Such statements are generally accompanied by words such as “intend,” “anticipate,” “believe,” “estimate,” “expect” or similar statements. Factors that could cause results or events to differ from current expectations include, among other things, the impact of price competition; the scarcity of qualified professionals; the impact of rapid technological and market change; loss of business or credit risk with major customers; technical risks on fixed-price projects; general industry and market conditions and growth rates; international growth and global economic conditions, including currency exchange rate fluctuations; and the impact of consolidations in the business services industry.

For additional information with respect to certain of these and other factors, please see the Company’s most recent annual report and other reports filed with the Ontario Securities Commission. Calian disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance can be given that actual results, performance or achievements expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them.

Calian · Head Office · 770 Palladium Drive · Ottawa · Ontario · Canada · K2V 1C8
Tel: 613.599.8600 · Fax: 613-592-3664 · General info email: info@calian.com

Recognition Highlights XCOM RAN’s Role in Transforming Warehouse Connectivity, Automation and Real-Time Operations by Delivering the Essential Infrastructure for Physical AI

Warehouse Technology Innovation of the Year

XCOM RAN Named “Warehouse Technology Innovation of the Year” in SupplyTech Breakthrough Awards
XCOM RAN Named “Warehouse Technology Innovation of the Year” in SupplyTech Breakthrough Awards

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) — XCOM RAN by Globalstar, a pioneer in next-generation private 5G technology, today announced it has been awarded “Warehouse Technology Innovation of the Year” in the 5th annual SupplyTech Breakthrough Awards program conducted by SupplyTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout technology companies, products and services in the global supply chain & logistics industry.

The annual SupplyTech Breakthrough Awards program rigorously evaluates the industry’s most innovative companies, technologies and solutions, recognizing only those that are setting new standards for operational excellence, partner engagement and supply chain growth. From procurement and omnichannel logistics to AI-driven analytics, automation and last-mile innovation, these breakthrough solutions are enabling supply chain companies to adapt faster, operate smarter and deliver exceptional customer experiences.

XCOM RAN is a comprehensive private 5G solution designed to support warehouse automation, robotics, intelligent inventory management, and connected mobile assets. With ultra-low latency and enterprise-grade reliability, it provides the foundational infrastructure needed to power physical AI across complex industrial environments. The end-to-end wireless connectivity solution enables devices in smart warehouses, manufacturing facilities, and logistics hubs to move seamlessly throughout a site while maintaining continuous, high-performance connectivity, regardless of facility size or number of connected devices.

“In a warehouse environment where a delayed signal can mean a stopped robot, a missed pick, or a worker safety incident, wireless limitations are unacceptable,” said Tamer Kadous, general manager, XCOM RAN Business Unit at Globalstar. “Our solution delivers up to four times greater network capacity compared to traditional private 5G deployments, making it uniquely suited for the high-density, always-on demands of modern warehouse automation. This award exemplifies what separates us with our purpose-built solution that delivers the connectivity foundation for Physical AI. Our focus is on developing wireless solutions that meet the modern era, empowering our customers to transform operationally, and to connect and communicate in smarter ways.”

The XCOM RAN solution combines hardware, software, and orchestration into a unified platform. Its differentiated software-defined Supercell architecture, based on O-RAN standards, significantly enhances capacity, real-time control, redundancy, and shared coverage—while reducing deployment complexity. It offers flexible network configurations using the n48, n53, or n78 spectrum bands, so mission-critical applications are never competing for spectrum with neighboring facilities or external users.

Warehouse operators benefit from faster time-to-operation, lower implementation costs, and a consistent network design that scales across multiple distribution centers and fulfillment facilities.

“XCOM RAN is not an incremental improvement to private wireless; it’s the next generation,” said Bryan Vaughn, Managing Director of SupplyTech Breakthrough Awards. “Modern industrial automation means physical AI is driving improved operational efficiencies in the warehousing and logistics industry. Autonomous mobile robots, AGVs, and robotic picking systems are becoming the new standard. By rethinking private 5G from the core to the device, XCOM RAN is primed for the AI-driven warehouse, giving warehouse operators the connectivity foundation they need to deploy advanced automation with confidence, scale operations efficiently, and stay competitive in an industry moving faster than ever.”

About XCOM RAN
XCOM RAN by Globalstar provides next-generation private 5G wireless connectivity that supports mobile robotics, connected workers and autonomous operations in industrial and mission-critical environments. Designed to support demanding physical AI and automation requirements, XCOM RAN delivers flawless connectivity and higher capacity through its differentiated software-defined, Supercell architecture operating in spectrum bands n48, n53 and n78. The solution simplifies deployment and management, providing the infrastructure required to power AI-driven operations at scale. For more information, visit www.xcomran.com and follow us on LinkedIn.

About SupplyTech Breakthrough
Part of the Tech Breakthrough organization, a leading global provider of market intelligence and recognition platforms for technology innovation and leadership, the SupplyTech Breakthrough Awards program is devoted to honoring innovation and market disruption in supply chain & logistics technologies, services, companies and products around the world. The annual SupplyTech Breakthrough Awards provide public recognition for the achievements of SupplyTech companies and products in categories including Inventory Management, Supply Chain Visibility, Transportation Management, Material Handling, IoT and Robotics, and more. For more information visit SupplyTechBreakthrough.com.

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Media Contact:
‍‍Janet Brumfield, IdealPR+ for XCOM RAN
janet@idealprplus.com
+1614-582-9636

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2c41f69f-7f11-4974-982d-1c7d56da5d56

VEON’s Beeline Kazakhstan Becomes First Operator in Country to Launch Starlink’s Satellite to Mobile Service

VEON’s Beeline Kazakhstan Becomes First Operator in Country to Launch Starlink's Satellite to Mobile Service
VEON’s Beeline Kazakhstan Becomes First Operator in Country to Launch Starlink’s Satellite to Mobile Service

Customers will be directly connected in cellular dead zones, giving a major boost to coverage

Almaty, New York and Dubai [29 September 2026] — VEON Ltd. (Nasdaq: VEON), a global digital operator, today announced that customers in Kazakhstan will now be able to use Starlink Mobile on their smartphones to access apps and messaging in areas without terrestrial mobile coverage. Beeline Kazakhstan, in partnership with Starlink, the world’s largest direct-to-device satellite network, enables resilient connectivity directly to smartphones without need for a satellite phone, antenna, or any other special equipment.

Service works best with a clear line of sight to the sky and can be used in mountains, remote locations, and highways outside cities. During the initial period, the service will be available to customers free to experience.

Customers can activate and manage Starlink Mobile, and access step-by-step guidance, through Janymda, Beeline Kazakhstan’s super app and leading digital platform. Integrating Starlink Mobile into Janymda gives customers a single, familiar place to manage their connectivity alongside the everyday digital services they already use.

The technology is of strategic importance and will help maintain connectivity in hard-to-reach areas and regions affected by natural disasters where terrestrial infrastructure has been damaged or is unavailable. In particular, satellite-to-mobile communications can be useful for emergency and rescue services, road and utility services, as well as tourists, mountaineers, travellers, and people working at sites in remote areas.

“Starlink Mobile is a powerful example of how connectivity can change lives, not just convenience. For someone stranded on a remote road or lost in the mountains, this could mean the difference between isolation and getting help. That’s the kind of impact VEON exists to deliver for people in Kazakhstan and across our markets,” said Kaan Terzioglu, CEO of VEON Group.

“This was a real team effort and close collaboration with the Ministry of Artificial Intelligence and Digital Development and with Starlink Mobile to get the technology right for our market. We’re proud to be the first operator in Kazakhstan to bring Starlink Mobile to market, helping people stay connected when it matters most,” said Jabbor Kayumov, CEO of Beeline Kazakhstan, commenting on the launch.

In November 2025, Beeline Kazakhstan and the Ministry of Artificial Intelligence and Digital Development signed a memorandum of cooperation with Starlink on the deployment of satellite-to-mobile technology, followed by the first practical trials in December.

About VEON
VEON is a digital operator that provides connectivity and digital services to over 150 million connectivity users and more than 228 million digital customers. Operating across five countries that are home to 550 million consumers, more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

About Beeline Kazakhstan
Beeline Kazakhstan serves 11.8 million customers with mobile connectivity and around one million with fixed internet services. Since 2018, the company has been executing its digital operator strategy. Over the past five years, leveraging its expertise in digital solution development, Beeline Kazakhstan has created an ecosystem of 60 internal and external products. Beeline Kazakhstan is majority-owned by VEON.

About Starlink Mobile
Starlink Mobile is the world’s only and largest constellation with 650 launched satellites in low-Earth orbit that delivers data, voice, video and messaging to devices in remote locations. Connecting millions of customers across six continents, Starlink satellites work with existing LTE phones wherever you can see the sky. Acting like a cell phone tower in space with the most advanced phased array antennas in the world that connect seamlessly across the Starlink network over lasers to any point in the globe, it enables network integration similar to a standard roaming partner. Starlink is the world’s largest 4G coverage provider and partners with Mobile Network Operators all over the world. Learn more here and follow @Starlink on X.

Forward-Looking Statements
This release contains “forward-looking statements,” as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, including in relation to Beeline Kazakhstan’s Starlink launch as well as the VEON group’s DTC strategy.

VEON media contact
pr@veon.com

Attachment

Ernexa selected for the Emerging Track, recognizing the Company among emerging
innovators in the cell and gene therapy sector

President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on
October 6, 2026, at 1:30 PM

Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101
in platinum-resistant ovarian cancer and its potential for broader expansion across
ovarian cancer and other solid tumor indications

Differentiated synthetic iMSC platform designed to provide a scalable, off-the-shelf
treatment solution without the need for patient-specific cell harvesting

ERNA-101 remains on track for planned IND submission in 2026

CAMBRIDGE, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that the Company has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, taking place October 5–7, 2026, in Mesa, Arizona. As part of this recognition, Chief Executive Officer Sanjeev Luther will deliver an Innovation Spotlight presentation on October 6, 2026, at 1:30 PM.

During the presentation, Mr. Luther will showcase Ernexa’s differentiated off-the-shelf induced mesenchymal stem cell, or iMSC, platform and the Company’s progress toward becoming a clinical-stage oncology company. The presentation will focus on ERNA-101, Ernexa’s lead oncology cell therapy candidate, and the Company’s focused strategy to establish clinical proof of concept initially in platinum-resistant ovarian cancer, with the potential to expand ERNA-101 across the ovarian cancer treatment continuum and into additional solid tumor indications.

Mr. Luther will also highlight the differentiated characteristics of Ernexa’s synthetic iMSC platform, which is designed to provide a scalable, off-the-shelf treatment solution without the need for patient-specific cell harvesting, as well as recently announced preclinical findings supporting the therapeutic potential of ERNA-101, including:

  • Independent validation of ERNA-101 combination therapy: In a larger, statistically robust study conducted by an independent contract research organization, ERNA-101 in combination with anti-PD-1 therapy achieved complete tumor clearance and long-term survival in two-thirds of treated animals. No complete responses were observed in either monotherapy group or the untreated control group. 
  • Complete tumor elimination and 100% long-term survival in an earlier ovarian cancer study: ERNA-101 in combination with PD-1 blockade achieved complete tumor clearance and 100% survival through the end of the study follow-up period, demonstrating the potential of ERNA-101 to enhance the activity of checkpoint inhibition in an immunologically cold tumor model.
  • Focused path toward clinical validation: Ernexa remains on track for a planned Investigational New Drug application submission for ERNA-101 in 2026. The Company believes establishing clinical proof of concept in ovarian cancer could provide a foundation for evaluating ERNA-101 across broader oncology indications.

Emerging Track Innovation Spotlight Presentation Details

Presenter: Sanjeev Luther, President & CEO
Company: Ernexa Therapeutics
Date: October 6, 2026
Time: 1:30 PM
Room: FLW Ballroom G

“We are honored that Ernexa has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, and we look forward to sharing the progress we are making with ERNA-101,” said Mr. Luther. “We believe this recognition reflects the potential of our differentiated approach to cell therapy as we prepare to transition ERNA-101 toward the clinic. Our strategy is focused on advancing one differentiated oncology candidate through a clear initial clinical pathway in platinum-resistant ovarian cancer, supported by a growing body of compelling preclinical evidence and independent validation of ERNA-101’s anti-tumor activity. As we advance toward planned clinical entry, we believe our synthetic, off-the-shelf iMSC platform provides a differentiated foundation to establish clinical proof of concept in ovarian cancer and potentially expand ERNA-101 into broader oncology indications. Most importantly, our focus remains on translating this strong preclinical foundation into a potential new treatment for patients who need better options.”

Presented by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa brings together senior executives, investors, strategic partners and other decision-makers from across the cell and gene therapy industry. The 2026 program is expected to feature more than 100 company presentations and more than 5,000 partnering meetings focused on advancing scientific, clinical and commercial innovation across the sector.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.